Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Axsome Therapeutics (AXSM) stock rallied 15% on news the company has settled patent litigation with Teva (TEVA) over a ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...

Shares of Axsome Therapeutics (NASDAQ: AXSM) are up on Tuesday. The jump comes as the S&P 500 (SNPINDEX: ^GSPC) lost 0.3% and ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Axsome Therapeutics (AXSM) is climbing nearly 4% after Swiss bank UBS increased its price target on the shares to $133 from ...

Teva has not raised capital since it acquired Actavis from Allergan in 2016 - a deal worth nearly $40 billion and for which ...

Who says hiking isn't romantic? Not us. This amazing hiking trail in South Dakota is perfect for couples.